CClinicalTrials.gg
TerminatedNCT04538261Updated Jun 3, 2025Results posted

Elevation of the Fetal Buttocks Prior to External Cephalic Version

An interventional study of Fetal Pillow insertion in Breech Presentation and External Cephalic Version, sponsored by AdventHealth. Terminated at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by AdventHealth · Not applicable, Interventional, and Treatment

Why this study was terminated
Not recruiting at the rate we thought it would.
Phase
Not applicable
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a prospective, randomized double-blind clinical trial evaluating the effect of a balloon device (Fetal Pillow) to elevate the fetal buttocks during external cephalic version procedures. Eligible study population: nulliparous pregnant women between 37-40 weeks estimated gestational age with a breech presenting fetus and no contraindications to external cephalic version.

Read the detailed description

Patients meeting inclusion criteria will be offered participation in this study. After performing an obstetric sonogram to determine fetal position, amniotic fluid status, fetal weight and placental location, the patient will be randomized to either placement of the Fetal Pillow balloon device with sham inflation (control arm) or placement of the device with inflation (study arm).

The researcher will show the patient the device, open the sterile container, and insert the device into the vagina per manufacturer's guidelines for all patients in the study. All patients will mark a line on a 100mm VAS to assess pre-insertion and post-insertion pain. The study physician will then obtain the assistance of a certified nurse midwife to inflate the device or perform a sham inflation. In order for the physician investigator to remain blinded, the physician will leave the room during the time of the inflation/sham inflation. A certified nurse midwife previously trained to inflate the device will perform the inflation or sham inflation per randomization. The assisting midwife will inflate the device with 180 mL of saline for those patients randomized to inflation. This will occur under a sheet so that the patient is blinded to the randomization scheme. If the patient is randomized to no inflation, the midwife will perform a sham inflation, also under a sheet. All patients will mark a line on a 100mm VAS to assess post-inflation/sham inflation pain. The assisting midwife then leaves the room, and the study physician reenters the room and proceeds with the external cephalic version (ECV) procedure.

Regardless of randomization, at this point the ECV procedure proceeds using normal routine. The ECV will be attempted up to four times and VAS will be assessed after each attempt. Once completed, all patients will also mark a line on a 100mm VAS to assess post-ECV pain.

The research physician will then remove the Fetal Pillow. Regardless of randomization, the procedure is completed per the usual routine of fetal monitoring, assessing for rupture of membranes, labor or bleeding, discussing post-procedure care, then discharge home (or, less likely, admitting for either observation or delivery).

The researcher will fill out the ECV portion of the data collection form. Data are collected later for delivery outcomes and costs for the mother and neonate.

02

Conditions studied

  • Breech Presentation
  • External Cephalic Version

Browse trials for

Keywords

  • Breech
  • Version
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Women delivering at AdventHealth Orlando campus.
  2. Breech presenting part as diagnosed by bedside sonography.
  3. No prior deliveries >/= 20 weeks gestational age.
  4. Pregnancy is between 37-40 weeks gestational age.
  5. Live fetus.
  6. Patient is >/= age 18.
  7. Patient speaks English or Spanish as primary language.
  8. Patient able to understand verbal and written consent

Exclusion criteria

Exclusion Criteria:

  1. Non-breech presentation (cephalic, transverse, oblique).
  2. More than 1 fetus.
  3. Cervical dilation of >/= 1cm.
  4. Prior uterine incision.
  5. Congenital uterine anomaly.
  6. Body mass index more than 40 kg/m2.
  7. Uterine fibroids causing soft tissue dystocia.
  8. Extended fetal neck.
  9. Oligohydramnios (4-quadrant amniotic fluid index \</= 5cm).
  10. Spontaneous rupture of membranes.
  11. Any contraindication to vaginal delivery.
  12. Intrauterine growth restriction (estimated fetal weight \</= 10%ile).
  13. Estimated fetal weight > /= 5,000 grams for non-diabetic patient or >/= 4,500 grams for patient with pre-existing or gestational diabetes, confirmed by ultrasound.
  14. Fetal gastroschisis.
  15. Fetal neural tube defect.
  16. Severe-range preeclampsia.
  17. Patient had regional anesthesia immediately prior to ECV.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
11 participants (actual)

Study arms

  • Sham comparator
    Control

    Non-inflation of the balloon device

    Device: Fetal Pillow insertion

  • Experimental
    Intervention

    Inflation of the balloon device

    Device: Fetal Pillow insertion

Interventions

  • DeviceFetal Pillow insertion

    Inflation of balloon device used to elevate fetal buttocks prior to performing external cephalic version procedure

05

What researchers measure

Primary outcomes

  1. Number of Participants Having Successful Conversion to Cephalic Presentation

    Successful conversion of breech fetus to cephalic presentation

    Time frame: Immediately upon completion of the ECV procedure

Secondary outcomes

  1. Cesarean Delivery

    Presence of cesarean delivery

    Time frame: Immediately after ECV procedure or during subsequent labor and delivery

  2. Fetal Presentation at Time of Delivery

    Cephalic presentation of the fetus during participant delivery

    Time frame: Labor and Delivery (approximately 12 hours)

  3. Cost of ECV Procedure and Hospital Stay (Mother)

    Cost of ECV procedure and hospital stay (mother)

    Time frame: ECV procedure and during labor, delivery, and immediate postpartum period (up to 42 days)

  4. Cost of ECV Procedure and Hospital Stay (Neonate)

    Cost of neonate's hospitalization after delivery

    Time frame: Birth to hospital discharge (up to 42 days)

  5. Shoulder Dystocia

    Presence of shoulder dystocia during delivery

    Time frame: Labor and Delivery (approximately 12 hours)

  6. Rupture of Membranes

    Presence of rupture of membranes after ECV procedure

    Time frame: Within 1 hour of ECV procedure

  7. Emergency Cesarean Delivery

    Need for emergency cesarean delivery during or after ECV procedure

    Time frame: During or within 1 hour of performing ECV procedure

  8. Pelvic Hematoma

    Development of a pelvic hematoma within 1 hour of ECV procedure

    Time frame: During or within 1 hour of performing ECV procedure

  9. Procedural Pain During Device Insertion

    Visual analogue pain score after insertion of balloon device (100mm visual analogue scale where 0 =no pain and 100=extreme pain).

    Time frame: Within 2 minutes after insertion of balloon device.

  10. Number of Attempts

    Number of attempted ECV procedures to convert fetus from breech to cephalic presentation

    Time frame: Immediately after ECV procedure

  11. Cost of Hospital Stay for ECV Procedure

    Total cost of the hospital stay for the ECV procedure

    Time frame: Patient arrival to labor unit for ECV procedure and discharge home (up to 72 hours)

  12. Procedural Pain Prior to Device Insertion.

    Baseline visual analogue pain score prior to insertion of balloon device (100mm visual analogue scale where 0 =no pain and 100=extreme pain).

    Time frame: Within 3 minutes prior to insertion of device.

  13. Procedural Pain After Inflation of Device or Sham Inflation.

    Visual analogue pain score after inflation or sham inflation of balloon device (100mm visual analogue scale where 0 =no pain and 100=extreme pain).

    Time frame: Within 1 minute after device inflation or sham inflation.

  14. Pain After External Cephalic Version Attempt.

    Visual analogue pain score after ECV procedure (100mm visual analogue scale where 0 =no pain and 100=extreme pain).

    Time frame: Within 2 minutes of ECV procedure completion.

06

Results

Posted Jun 3, 2025

Participant flow

Participant flow — Overall Study
MilestoneControlIntervention
Started65
Completed65
Not completed00

Outcome measures

PrimaryNumber of Participants Having Successful Conversion to Cephalic Presentation

Successful conversion of breech fetus to cephalic presentation

Time frame:
Immediately upon completion of the ECV procedure
Reported as:
Count of participants · Participants
Number of Participants Having Successful Conversion to Cephalic Presentation
ParticipantsControlIntervention
Number of Participants Having Successful Conversion to Cephalic Presentation32
SecondaryCesarean Delivery

Presence of cesarean delivery

Time frame:
Immediately after ECV procedure or during subsequent labor and delivery
Reported as:
Count of participants · Participants
Cesarean Delivery
ParticipantsControlIntervention
Cesarean Delivery00
SecondaryFetal Presentation at Time of Delivery

Cephalic presentation of the fetus during participant delivery

Time frame:
Labor and Delivery (approximately 12 hours)
Reported as:
Count of participants · Participants
Fetal Presentation at Time of Delivery
ParticipantsControlIntervention
Fetal Presentation at Time of Delivery33
SecondaryCost of ECV Procedure and Hospital Stay (Mother)

Cost of ECV procedure and hospital stay (mother)

Time frame:
ECV procedure and during labor, delivery, and immediate postpartum period (up to 42 days)

No measurements were reported for this outcome.

SecondaryCost of ECV Procedure and Hospital Stay (Neonate)

Cost of neonate's hospitalization after delivery

Time frame:
Birth to hospital discharge (up to 42 days)

No measurements were reported for this outcome.

SecondaryShoulder Dystocia

Presence of shoulder dystocia during delivery

Time frame:
Labor and Delivery (approximately 12 hours)
Reported as:
Count of participants · Participants
Shoulder Dystocia
ParticipantsControlIntervention
Shoulder Dystocia00
SecondaryRupture of Membranes

Presence of rupture of membranes after ECV procedure

Time frame:
Within 1 hour of ECV procedure
Reported as:
Count of participants · Participants
Rupture of Membranes
ParticipantsControlIntervention
Rupture of Membranes00
SecondaryEmergency Cesarean Delivery

Need for emergency cesarean delivery during or after ECV procedure

Time frame:
During or within 1 hour of performing ECV procedure
Reported as:
Count of participants · Participants
Emergency Cesarean Delivery
ParticipantsControlIntervention
Emergency Cesarean Delivery00
SecondaryPelvic Hematoma

Development of a pelvic hematoma within 1 hour of ECV procedure

Time frame:
During or within 1 hour of performing ECV procedure
Reported as:
Count of participants · Participants
Pelvic Hematoma
ParticipantsControlIntervention
Pelvic Hematoma00
SecondaryProcedural Pain During Device Insertion

Visual analogue pain score after insertion of balloon device (100mm visual analogue scale where 0 =no pain and 100=extreme pain).

Time frame:
Within 2 minutes after insertion of balloon device.
Reported as:
Mean · units on a scale
Procedural Pain During Device Insertion
units on a scaleControlIntervention
Procedural Pain During Device Insertion29 (0 to 69)59.6 (3 to 85)
SecondaryNumber of Attempts

Number of attempted ECV procedures to convert fetus from breech to cephalic presentation

Time frame:
Immediately after ECV procedure
Reported as:
Mean · Number of attempts
Number of Attempts
Number of attemptsControlIntervention
Number of Attempts2.3 ± 1.42.6 ± 1.5
SecondaryCost of Hospital Stay for ECV Procedure

Total cost of the hospital stay for the ECV procedure

Time frame:
Patient arrival to labor unit for ECV procedure and discharge home (up to 72 hours)

No measurements were reported for this outcome.

SecondaryProcedural Pain Prior to Device Insertion.

Baseline visual analogue pain score prior to insertion of balloon device (100mm visual analogue scale where 0 =no pain and 100=extreme pain).

Time frame:
Within 3 minutes prior to insertion of device.
Reported as:
Mean · units on a scale
Procedural Pain Prior to Device Insertion.
units on a scaleControlIntervention
Procedural Pain Prior to Device Insertion.4.8 (0 to 12)10.4 (0 to 30)
SecondaryProcedural Pain After Inflation of Device or Sham Inflation.

Visual analogue pain score after inflation or sham inflation of balloon device (100mm visual analogue scale where 0 =no pain and 100=extreme pain).

Time frame:
Within 1 minute after device inflation or sham inflation.
Reported as:
Mean · units on a scale
Procedural Pain After Inflation of Device or Sham Inflation.
units on a scaleControlIntervention
Procedural Pain After Inflation of Device or Sham Inflation.22 (0 to 75)31 (4 to 60)
SecondaryPain After External Cephalic Version Attempt.

Visual analogue pain score after ECV procedure (100mm visual analogue scale where 0 =no pain and 100=extreme pain).

Time frame:
Within 2 minutes of ECV procedure completion.
Reported as:
Mean · units on a scale
Pain After External Cephalic Version Attempt.
units on a scaleControlIntervention
Pain After External Cephalic Version Attempt.38.7 (10 to 60)29.2 (0 to 58)

Adverse events

Collected over 1 hour after completion of ECV procedure until discharge after delivery (average of 3.5 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control0/6 (0%)0/6 (0%)0/6 (0%)
Intervention0/5 (0%)0/5 (0%)0/5 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)ControlInterventionTotal
Mean30.5 ± 6.228.6 ± 3.929.5 ± 5.1
Sex: Female, Male
Sex: Female, Male(Participants)ControlInterventionTotal
Female6511
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ControlInterventionTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American112
White549
More than one race000
Unknown or Not Reported000
07

Study locations

1 site
  • AdventHealth Orlando
    Orlando, Florida 32804, United States
08

References and documents

Publications

  • External Cephalic Version: ACOG Practice Bulletin, Number 221. Obstet Gynecol. 2020 May;135(5):e203-e212. doi: 10.1097/AOG.0000000000003837. PubMed 32332415 ↗
  • Seal SL, Dey A, Barman SC, Kamilya G, Mukherji J, Onwude JL. Randomized controlled trial of elevation of the fetal head with a fetal pillow during cesarean delivery at full cervical dilatation. Int J Gynaecol Obstet. 2016 May;133(2):178-82. doi: 10.1016/j.ijgo.2015.09.019. Epub 2016 Jan 15. PubMed 26868074 ↗
  • Hofmeyr GJ, Kulier R, West HM. External cephalic version for breech presentation at term. Cochrane Database Syst Rev. 2015 Apr 1;2015(4):CD000083. doi: 10.1002/14651858.CD000083.pub3. PubMed 25828903 ↗
  • Kok M, Cnossen J, Gravendeel L, van der Post J, Opmeer B, Mol BW. Clinical factors to predict the outcome of external cephalic version: a metaanalysis. Am J Obstet Gynecol. 2008 Dec;199(6):630.e1-7; discussion e1-5. doi: 10.1016/j.ajog.2008.03.008. Epub 2008 May 23. PubMed 18456227 ↗
  • Weiniger CF, Ginosar Y, Elchalal U, Sharon E, Nokrian M, Ezra Y. External cephalic version for breech presentation with or without spinal analgesia in nulliparous women at term: a randomized controlled trial. Obstet Gynecol. 2007 Dec;110(6):1343-50. doi: 10.1097/01.AOG.0000295605.38175.7b. PubMed 18055730 ↗

Study documents

  • Protocol and statistical analysis plan · Nov 23, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — IPD will not be shared outside of research team.

09

Registry details

Key details

Study ID
NCT04538261
Lead sponsor
AdventHealth
Responsible party
Sponsor
First posted
Sep 4, 2020
Start date
Nov 1, 2020
Primary completion
Jan 31, 2023
Completion
Jan 31, 2023
Results posted
Jun 3, 2025
Last update
Jun 3, 2025

Study contacts

David A Hill, MD
principal investigator · AdventHealth
Ariana Mora
study director · AdventHealth

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion